KALV
NasdaqKalVista Pharmaceuticals, Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2024-04-30
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$1.5M
2017
$8.4M
2018
$16.1M
2019
$12.7M
2020
$50.0M
2024
Snapshot
SEC EDGAR · FY 2024-04-30Revenue$50.0M
Net Income$-126.6M
Gross Profit—
Oper Income$-188.0M
EPS (dil)$-3.69
Rev/sh$0.94
FCF/sh$-2.88
Book/sh$3.88
Gross M—
Oper M-376.0%
Profit M-253.3%
FCF M-306.7%
ROE-61.3%
ROA-53.8%
ROIC-104.2%
R&D/Rev143.4%
Rev Y/Y294.0%
Rev 3Y CAGR81.3%
EPS Y/Y-7.3%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+35%
Current Ratio9.90
Quick Ratio9.72
Debt/Eq0.03
Int Coverage-32.5×
Net Debt$26.5M cash
Total Debt$5.3M
Cash & Eq$31.8M
Total Assets$235.4M
Oper CF$-152.9M
Capex$434,000
Free CF$-153.3M
Buybacks—
Equity$206.6M
Liabilities$28.8M
Shs Outstand0.05B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2017 | FY2018 | FY2019 | FY2020 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $8.4M | $16.1M | $12.7M | $50.0M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-22.3M | $-18.7M | $-29.8M | $-40.5M | $-140.4M |
| Net Income | $-18.6M | $-15.8M | $-20.8M | $-29.1M | $-126.6M |
| Diluted EPS | $-4.47 | $-1.53 | $-1.38 | $-1.64 | $-3.44 |
| Operating Cash Flow | $-23.7M | $10.6M | $-36.4M | $-44.8M | $-89.2M |
| Free Cash Flow | $-23.8M | $9.1M | $-37.4M | $-45.0M | $-89.3M |
COMMUNITY · $KALV0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.